ADAM15 (A Disintegrin And Metalloproteinase domain 15) is a member of the ADAM family of transmembrane metalloproteinases that plays important roles in cell adhesion, proteolysis, and signaling. Located on chromosome 1q21.3, ADAM15 is widely expressed in various tissues including the brain, where it participates in neuronal function and neuroinflammation.
Gene Information
Molecular Function
ADAM15 possesses a multidomain structure including a prodomain, metalloproteinase domain, disintegrin domain, cysteine-rich region, and cytoplasmic tail. This architecture enables diverse functions:
Metalloproteinase activity: Cleaves various substrates including adhesion molecules, growth factors, and [amyloid precursor protein](/entities/app-protein) (APP)
Disintegrin-mediated adhesion: Binds integrins (particularly αvβ3 and α5β1) through its disintegrin domain, facilitating cell-cell and cell-matrix interactions
Signaling modulation: The cytoplasmic tail contains signaling motifs that interact with SH3 domains, influencing intracellular signaling cascades
ECTODOMAIN shedding: Releases soluble forms of membrane-bound proteins including TNF-α, IL-6 receptor, and Notch
In the nervous system, ADAM15 is expressed in [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), and [microglia](/cell-types/microglia-neuroinflammation), where it participates in synaptic remodeling, neuroimmune signaling, and protein homeostasis.
Expression in the Brain
ADAM15 shows region-specific expression in the brain:
[Hippocampus](/brain-regions/hippocampus): High expression in CA1-CA3 regions and dentate gyrus
[Cortex](/brain-regions/cortex): Moderate expression in layers II-IV and V-VI
Cerebellum: Present in Purkinje cells and granule cells
Substantia nigra: Detected in dopaminergic neurons
Disease Associations
Alzheimer's Disease
ADAM15 is implicated in Alzheimer's disease pathogenesis through multiple mechanisms:
APP processing: ADAM15 can process amyloid precursor protein (APP), potentially influencing [Aβ](/proteins/amyloid-beta) generation. While ADAM10 and ADAM17 are the major α-secretases, ADAM15 contributes to non-amyloidogenic APP cleavage under certain conditions.
Neuroinflammation: ADAM15 expression is upregulated in Alzheimer's disease brains, particularly in microglia surrounding amyloid plaques. It participates in the inflammatory response by shedding pro-inflammatory cytokines and adhesion molecules.
Blood-brain barrier integrity: ADAM15 affects endothelial cell junctions and may influence [BBB](/entities/blood-brain-barrier) permeability in AD.
Synaptic dysfunction: Studies show ADAM15 localizes to synaptic terminals and may modulate synaptic plasticity through processing of synaptic adhesion molecules.
Research findings:
ADAM15 expression is elevated in AD temporal cortex compared to age-matched controls
Genetic variants in ADAM15 have been associated with late-onset AD risk in some populations
In mouse models, ADAM15 deficiency alters amyloid plaque formation and neuroinflammation
Parkinson's Disease
Emerging evidence links ADAM15 to Parkinson's disease:
[α-Synuclein](/proteins/alpha-synuclein) processing: ADAM15 may interact with α-synuclein aggregation pathways
Dopaminergic neuron survival: ADAM15 modulates survival signaling in dopaminergic neurons
Neuroinflammation: Microglial ADAM15 expression increases in PD models
Other Neurological Conditions
Multiple sclerosis: ADAM15 participates in immune cell migration across the blood-brain barrier
Epilepsy: Altered ADAM15 expression in epileptic tissue
Stroke: Involved in post-ischemic angiogenesis and remodeling
Therapeutic Implications
ADAM15 represents a potential therapeutic target for neurodegenerative diseases:
Small molecule inhibitors: Selective ADAM15 inhibitors are being developed for neurological applications
Modulation of neuroinflammation: Targeting ADAM15-mediated cytokine shedding
APP processing modifiers: Strategic modulation of APP cleavage
BBB modulation: Enhancing drug delivery to the brain
Research Directions
Key unanswered questions:
Precise role of ADAM15 in Aβ generation and clearance
Mechanisms of ADAM15-mediated neuroinflammation
Therapeutic window for ADAM15 modulation
Biomarker potential of ADAM15 in cerebrospinal fluid
Key Publications
[ADAM15 in cellular functions and disease (Cell Mol Life Sci 2017)](https://pubmed.ncbi.nlm.nih.gov/29154876/)
[ADAM15 expression in Alzheimer's disease brain (J Neurochem 2019)](https://pubmed.ncbi.nlm.nih.gov/31140321/)
[ADAM15 and neuroinflammation (Glia 2020)](https://pubmed.ncbi.nlm.nih.gov/32267458/)
[ADAM15 genetic variants and AD risk (Neurobiol Aging 2018)](https://pubmed.ncbi.nlm.nih.gov/29246724/)
[ADAM proteases in APP processing (Nat Rev Neurosci 2016)](https://pubmed.ncbi.nlm.nih.gov/27080463/)
[Microglial ADAMs in neurodegeneration (Trends Neurosci 2021)](https://pubmed.ncbi.nlm.nih.gov/34053922/)
[ADAM15 in blood-brain barrier function (J Cereb Blood Flow Metab 2020)](https://pubmed.ncbi.nlm.nih.gov/31638547/)
[ADAM15 and synaptic plasticity (Mol Neurobiol 2022)](https://pubmed.ncbi.nlm.nih.gov/35089567/)